Inventiva SACA

Inventiva to Participate in Upcoming September Investor Conferences

04 9 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

11 8 2025 13:00:00 提供 Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

31 7 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

29 7 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

09 7 2025 13:05:00 提供 Nasdaq GlobeNewswire

Inventiva receives $10 million milestone payment from CTTQ

07 7 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

02 7 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

10 6 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

27 5 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports 2025 First Quarter Financial Information¹

22 5 2025 23:30:00 提供 Nasdaq GlobeNewswire

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

22 5 2025 23:00:00 提供 Nasdaq GlobeNewswire

Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

22 5 2025 05:00:00 提供 Nasdaq GlobeNewswire

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

04 5 2025 23:30:00 提供 Nasdaq GlobeNewswire

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

30 4 2025 13:00:00 提供 Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

30 4 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

24 4 2025 13:01:28 提供 Nasdaq GlobeNewswire

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

15 4 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

01 4 2025 14:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports its 2024 full year results and provides a business update

26 3 2025 13:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

19 3 2025 13:00:00 提供 Nasdaq GlobeNewswire